DaVita(US:DVA) Financial Modeling Prepยท2025-10-29 15:00Core Insights - DaVita Inc. is a leading provider of kidney dialysis services, operating a vast network of outpatient centers and offering various healthcare services [1] Price Target Trends - The consensus price target for DaVita has decreased from $145.67 last quarter to $144.50 last month, indicating a slight reduction in analyst optimism [2] - In the medium term, the price target has dropped from $155.25 last year to $145.67 last quarter, reflecting potential changes in market conditions or company performance [3] - Over the long term, the consensus price target has declined by approximately $10.75 from last year to the current period, possibly due to broader healthcare sector challenges or company-specific issues [4] Financial Performance - DaVita has reduced its share count by over 10% in the past six months, despite facing a 50% year-over-year increase in interest expenses [3][6] - The company experienced a 1.1% year-over-year decline in volumes in the U.S. during Q2 2025, attributed to missed treatments from a severe flu season and a cyber attack [5] International Growth - DaVita's international revenues have grown by 36% year-over-year, indicating significant potential for expansion outside the U.S. [4][6] Acquisition and Regulatory Aspects - DaVita is awaiting regulatory approval for an acquisition from Fresenius Medical Care AG in Brazil [5]